Network origin in Gabriela Burian first degree
Entity | Entity type | Industry | |
---|---|---|---|
Breye Therapeutics ApS
Breye Therapeutics ApS Pharmaceuticals: MajorHealth Technology Breye Therapeutics ApS is a biopharmaceutical company based in Copenhagen, Denmark. The Danish company develops novel, oral ophthalmology drugs to address the needs of millions of patients suffering from deteriorating vision due to diabetic retinopathy (DR) or age-related macular degeneration (AMD). Breye Therapeutics' lead program with Danegaptide has a clinically de-risked safety profile and potential for a short and well-accepted clinical regulatory pathway. The company aims to provide less burdensome and more effective treatments for DR and AMD patients, which are currently treated with unpopular intravitreal injections directly into the eye. The company was founded in 2019, and the CEO is Ulrik Mouritzen.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Gabriela Burian via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
GIMV NV | Investment Managers | Corporate Officer/Principal | |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal | |
Maastricht University | College/University | Doctorate Degree | |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Chief Executive Officer | |
CropDesign NV
CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director/Board Member | |
ABLYNX | Biotechnology | Director/Board Member | |
Gimv Life Sciences
Gimv Life Sciences Investment ManagersFinance Gimv Life Sciences (Gimv-LS) is the venture capital division of Belgium's Gimv NV (XB: GIMB), an investment firm founded in 1980. Based in Antwerp, Gimv-LS manages a variety of funds which focus on investing in European companies in the life sciences / biotech sector, including the Biotech Fonds Vlaanderen, which was established at the request of the Flemish Region to provide venture capital to existing and start-up medium and large-sized companies in the Flemish biotechnology sector. | Investment Managers | Corporate Officer/Principal | |
MyCartis NV
MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member | |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member | |
Janssen Pharmaceutica NV
Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium. | Pharmaceuticals: Major | Corporate Officer/Principal | |
DYSIS Medical Ltd.
DYSIS Medical Ltd. Medical SpecialtiesHealth Technology DySIS Medical Ltd. designs, develops, manufactures, and markets medical imaging systems. Its imaging systems assist clinicians with non-invasive, in-vivo detection of cancerous and pre-cancerous lesions and provides tools to aid medical practitioners in the detection, grading, and documentation of cervical neoplasia. The company was founded by Costas Balas in 2002 and is headquartered in Livingston, the United Kingdom. | Medical Specialties | Director/Board Member | |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
FlandersBio vzw
FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Miscellaneous Commercial Services | Director/Board Member | |
Merck Serono Ltd.
Merck Serono Ltd. Miscellaneous Commercial ServicesCommercial Services Merck Serono Ltd. provides research and development services and manufactures medicinal drugs. The company is headquartered in Middlesex, the United Kingdom. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Lundbeckfonden Ventures
Lundbeckfonden Ventures Investment ManagersFinance Lundbeckfonden Ventures (Lundbeckfonden Ventures) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2009 and is headquartered in Copenhagen, Denmark. | Investment Managers | Private Equity Investor | |
Ovizio Imaging Systems SA
Ovizio Imaging Systems SA Electronic ComponentsElectronic Technology Ovizio Imaging Systems SA develops and markets imaging systems and sensors. Its microscopes include iLine F, iLine M, iLine S and QMod. The company was founded by Catherine Yourassowsky, Frank Dubois, Philip Mathuis and Serge Jooris in December 2009 and is headquartered in Brussels, Belgium. | Electronic Components | Director/Board Member | |
KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Chief Executive Officer | |
University of Antwerp | College/University | Graduate Degree | |
Acesion Pharma ApS
Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman | |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
SPERO THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Bioskills BV
Bioskills BV Miscellaneous Commercial ServicesCommercial Services Bioskills BVBA provides business services. The private company is based in Waasmunster, Belgium. The Belgian company was founded by Jim van Heusden. | Miscellaneous Commercial Services | Chief Executive Officer | |
Biogazelle NV
Biogazelle NV BiotechnologyHealth Technology Biogazelle NV is a research and development stage biotechnology firm. It specializes in ribonucleic acid for next generation diagnostics in the field of oncology and other diseases. The company was founded by Jan Hellemans and Jo Vandesompele in 2007 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member | |
Acacia Pharma, Inc.
Acacia Pharma, Inc. Medical DistributorsDistribution Services Part of Eagle Pharmaceuticals, Inc., Acacia Pharma, Inc. distributes pharmaceutical products. The company is based in Dover, DE. | Medical Distributors | Director/Board Member | |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Director/Board Member | |
ReWind Therapeutics NV
ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | Pharmaceuticals: Major | Chairman | |
Hemab ApS
Hemab ApS BiotechnologyHealth Technology Hemab ApS develops antibodies for the treatment of rare bleeding disorders. The company is based in Copenhagen, Denmark. The Danish company was founded in 2019 by Johan Henrik Faber. Benny Sorensen has been the CEO of the company since 2020. | Biotechnology | Director/Board Member | |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Miscellaneous Commercial Services | Director/Board Member |
Statistics
International
Belgium | 15 |
Denmark | 6 |
Sweden | 6 |
United States | 5 |
Netherlands | 4 |
Sectoral
Health Technology | 20 |
Finance | 7 |
Commercial Services | 7 |
Consumer Services | 3 |
Electronic Technology | 2 |
Operational
Director/Board Member | 24 |
Chairman | 5 |
Corporate Officer/Principal | 4 |
Chief Executive Officer | 4 |
Private Equity Investor | 2 |
Most connected contacts
Insiders | |
---|---|
Jim van Heusden | 22 |
Jørgen Søberg Petersen | 8 |
Johan Kördel | 8 |
Ulrik Mouritzen | 1 |
- Stock Market
- Insiders
- Gabriela Burian
- Company connections